Lenalidomide in relapsed refractory myeloma patients: Impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium

Acta Clinica Belgica

Volumn 66, Issue 5, 2011, Pages 371-375

  Delforge, M ^a   Michiels, A ^a   Doyen, C ^b   Kentos, A ^c   Van Droogenbroeck, J ^d   Offner, F ^e   Bries, G ^f   Demuynck, H ^g   Vekemans, M C ^h   Meuleman, N ⁱ   Mineur, P ^j   Ravoet, C ^k   Depryck, B ^l   Van De Velde, A ^m   Pierre, P ⁿ   Wu, K L ^o   Schots, R ^p  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^c ERASME HOSPITAL   (Belgium)

^d Afdeling Hematologie   (Belgium)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f Afdeling Hematologie   (Belgium)

^g Heilig Hart Ziekenhuis   (Belgium)

^h Service d'hématologie HÔpital Erasme   (Belgium)

ⁱ JULES BORDET INSTITUTE   (Belgium)

^j Clinique Saint Joseph   (Switzerland)

^k Hôpital de Jolimont   (Australia)

^l Centre Hospitalier Regional de La Citadelle   (Belgium)

^m ANTWERP UNIVERSITY HOSPITAL   (Belgium)

ⁿ Clinique du Sud Luxembourg   (Belgium)

^o ZNA Stuivenbergziekenhuis   (Belgium)

^p UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

more..

Author keywords

Bortezomib; Lenalidomide; Multiple myeloma; Thalidomide

Indexed keywords

ACETYLSALICYLIC ACID; BORTEZOMIB; COUMARIN; DEXAMETHASONE; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; THALIDOMIDE;

ADULT; AGED; ARTICLE; BELGIUM; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; RASH; RELAPSED REFRACTORY MULTIPLE MYELOMA; REMISSION; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BELGIUM; BORONIC ACIDS; DEXAMETHASONE; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PYRAZINES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84555196851     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.2143/ACB.66.5.2062589     Document Type: Article

References (15)

1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008; 111: 2962-2972.
2. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of Bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617. (Pubitemid 36741588)
3. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
4. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108: 3458-3464.
5. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-2132. (Pubitemid 350146107)
6. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133-2142. (Pubitemid 350146108)
7. Wang M, Dimopoulos MA, Chen C, et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 2008; 12: 4445-4451.
8. Kneppers E, Lokhorts HM, Eeltink CM, et al. Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program. Clin Lymphoma Myeloma Leuk 2010 ; 10: 138-143.
9. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998: 102: 1115-1123. (Pubitemid 28435189)
10. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006; 20: 1467-1473. (Pubitemid 44264086)
11. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial. Lancet Oncol 2010; 11: 29-37.
12. Stadtmauer EA, Weber DM, Niesvizky R, et al. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol 2009; 82: 426-432.
13. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010; 116: 679-686.
14. Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: A report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 2007; 25: 4459-4465. (Pubitemid 350063804)
15. Chen C, Reece DE, Siegel D, et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol 2009; 146: 164-170.